Oculis S.A.

Founded in 2017 and based in Lausanne, Switzerland, Oculis S. A. is a biopharmaceutical company that develops topical eye treatments for the anterior and posterior sections of the eye affected by ophthalmic diseases such as diabetic macular edema. The company emerged from a research collaboration of ophthalmologist Prof.

Einar Stefánsson and pharmacist and chemist Prof. Thorsteinn Loftsson. Its first product OPTIREACH® achieved animal proof of concept in the same year. In October 2022, Oculis S.

A agreed to merge with European Biotech Acquisition Corp. a SPAC Vehicle, for an undisclosed amount. As part of the transaction, The combined company will receive a USD 91 million in a PIPE deal from LSP 7, Earlybird, Novartis Venture Fund, Tekla Capital Management LLC, Pivotal Life Sciences and VI Partners and other unspecified investors. In 2023, the company went public on NASDAQ (ticker: OCS).

As of 2023, the company has 8 pipelines under development, of which two are in phase III. Its pipeline OCS-01 is based on the OPTIREACH technology, OCS-02 is a single-chain antibody fragment against TNFa and OCS-05 is a novel serum-glucocorticoid-regulated protein kinase 2 activator peptidomimetic small molecule.